Sunday, November 20, 2011 5:03:56 PM
Compensated Awareness Post View
Disclaimer
TPIV DD !!!! >>>
Contact Info
2815 Eastlake Avenue East
Suite 300
Seattle, WA 98102
United States
Phone: 206-336-5560
Company Description:
www.tapimmune.com TapImmune Inc., a development stage biotechnology company, focuses on the development and marketing of products specializing in the application of discoveries in cellular and molecular immunology and cancer biology to the development of proprietary therapeutics aimed at the treatment and eradication of cancer and prevention of infectious diseases. The company’s technologies are based on an understanding of the function of a protein pump known as ‘TAP’, which is located within cells and which is essential to the processing of foreign (microbial) or autologous antigens, and subsequent presentation to the immune system for eradication of the cancer or infected cell. Products and Technology in Development The company has developed its TAP Cancer Vaccine at the UBC Biomedical Research Centre under an agreement. This therapeutic cancer vaccine candidate, to be tested in preclinical toxicology studies, would include the patented use of the TAP-1 gene to restore the TAP protein, with the objective being to develop the TAP technology as a therapeutic cancer vaccine that would restore the normal immune recognition of cancer cells. The company has completed small animal pre-clinical animal testing of its TAP Cancer Vaccine to the extent that is required as a prerequisite for further preclinical toxicology analysis and investigational new drug (IND) application to the United States Federal Drug Administration. Strategic Alliances The company has entered into a five-year research license and option agreement with Crucell Holland B.V. (Crucell), whereby Crucell granted it a worldwide license for the research use of its packaging cell (PerC6) technology. The company signed a license agreement with the National Institute of Health (USA) for the use of the Modified Vaccinia Ankora (MVA) virus for the development of vaccines. It would license this technology for the development of prophylactic vaccines against infectious diseases. Competition The company’s major competitors include CellGenSys Inc., Dendreon Corp., Genzyme Molecular Oncology, and Transgene S.A. Significant Events In June 2010, the company has signed a licensing option agreement with Mayo Clinic Rochester for clinical development of a breast cancer vaccine technology. On August 4, 2010, TapImmune, Inc. announced that the company has signed a research and technology license option agreement with Mayo Clinic Rochester for the development of a smallpox vaccine technology.
Market / Customers
The company is currently developing TAP based vaccines for the oncology and prophylactic market. The global vaccine market is expected to grow from $13 billion in 2007 to $21 billion in 2010.
Website: http://www.tapimmune.com
Board maembers >>>> http://investing.businessweek.com/research/stocks/people/board.asp?ticker=TPIV:US
Latest news >>> http://www.biospace.com/company_profile.aspx?CompanyId=1004132
Ceo Profile:
Dr. Glynn Wilson, Ph.D. has been Executive Chairman of TapImmune, Inc. since June, 2009 and serves as its Chief Executive Officer. Dr. Wilson serves as President and Chief Executive Officer of Auriga Pharmaceuticals, a Speciality Pharmaceutical Company. Dr. Wilson serves as President of GW Group. He served as President of Auriga Laboratories Inc. until May 17, 2006 and its Chief Scientific Officer until August 25, 2006. He served as a Head for Drug Delivery of SmithKline ... Beecham Pharmaceuticals and Executive Vice-President for R&D of Tacora Corporation, he was responsible for conceiving and developing lead products (currently in Phase II clinical development), and providing leadership in the merging of Tacora Corporation with Access Pharmaceuticals. Dr. Wilson was the Worldwide Head of Drug Delivery of SmithKline Beecham from 1989 to 1994, and the Chief Scientific Officer of Tacora Corporation from 1994 to 1997. Dr. Wilson was the Vice-President, R&D, at Access Pharmaceuticals from 1997 to 1998, and the President and Chief Executive Officer of PharmaSpec Corporation from 1999 to 2000. In addition, he was a founding member of the Advanced Drug Delivery Group at Ciba-Geigy. He has been an adjunct professor, Pharmaceutics and Pharmaceutical Chemistry, at the University of Utah since 1994. He serves as Chairman of Medical and Clinical Board of Posh Cosmeceuticals Inc. He served as Chairman of the Board of Auriga Laboratories Inc. until May 17, 2006. He has been a Director of Genemax Corp. since February 2005 and TapImmune, Inc. since February 2005. He served as Director of Auriga Laboratories Inc. until May 17, 2006. He was a faculty member at Rockefeller University, New York, in the laboratory of the Nobel Laureates, Stanford Moore and William Stein from 1974 to 1979. Dr. Wilson obtained his Ph.D. in Biochemistry, at Heriot-Watt University, Edinburgh in 1972
Former Chairman and President
Auriga Laboratories Inc.
2005-Present
Executive Chairman, Chief Executive Officer, Member of Audit Committee and Member of Compensation Committee
TapImmune, Inc.
Ceo answers questions : >>> http://www.smallcapnetwork.com/TPIV-shows-significant-potential-plus-a-forward-looking-FDA-trade-catalyst/s/via/367/article/view/p/mid/1/id/53/
University, New York, in the laboratory of the Nobel Laureates, Stanford Moore and William Stein from 1974 to 1979. Dr. Wilson obtained his Ph.D. in Biochemistry, at Heriot-Watt University, Edinburgh in 1972
Former Chairman and President
Auriga Laboratories Inc.
2005-Present
Executive Chairman, Chief Executive Officer, Member of Audit Committee and Member of Compensation Committee
TapImmune, Inc.
Ceo answers questions : >>> http://www.smallcapnetwork.com/TPIV-shows-significant-potential-plus-a-forward-looking-FDA-trade-catalyst/s/via/367/article/view/p/mid/1/id/53/
"US Patent Office has issued Patent 7,994,146 entitled "Method of Enhancing an Immune Response". >>> http://www.patentgenius.com/patent/7994146.html
http://www.globenewswire.com/newsroom/news.html?d=236218
With the World Health Organization's recent vocal announcements of growing threats that multidrug-resistant and extensively drug-resistant forms of tuberculosis are spreading at an alarming rates in Europe, investors have once again begun to pay more attention to TPIV, which holds promise as both an anti-cancer and bio-defense play. TapImmune continues working with the likes of the Mayo Clinic and Aeras Foundation on vaccine candidates in both Cancer and Infectious Diseases.
The company has been quietly building solid relationships within industry because of the relevance of the TAP technology and BioMedReports continues to expect positive developments from the firm, particularly with CEO Dr. Glynn Wilson on the verge of presenting data from the clinic on TAP levels and its affect on disease progression. There is growing evidence now from around the world showing that TAP is indeed a key component in the antigen presentation process and where it is lacking or down regulated, disease progresses and prognosis is worse.
The Seattle based company's TAP-based prophylactic vaccine -- which initial tests indicate may increase the efficacy of targeted prophylactic vaccines by up to 1000 times -- may significantly improve the efficacy of many current prophylactic vaccines and enhance the creation of new ones in the fight against many pandemic infectious diseases.
A next generation smallpox vaccine is currently in preclinical development and the company has been busy working with Gregory Poland, the head of the Mayo Clinic's Vaccine Research Group, who is working to unite the fields of genomics and vaccinology. That work has come about, in part, because Poland and others have never been fully pleased with the existing vaccine paradigm.
Share StructureMarket Value1 $11,234,573 a/o Nov 18, 2011
Shares Outstanding 46,810,721 a/o Aug 01, 2011
http://www.otcmarkets.com/stock/TPIV/company-info
TPIV fact sheet PDF >>>> http://www.tapimmune.com/_resources/fact_sheet_nov_10.pdf
TPIV sec of state ACTIVE !!! http://nvsos.gov/sosentitysearch/CorpDetails.aspx?lx8nvq=yBFGvR8m9YhhFRCpanNMrQ%253d%253d&nt7=0
Chairman and CEO, Dr. Glynn Wilson, is an invited speaker at BIT's 2nd Annual World Congress on Immunodiseases and Therapy to be held in Guangzhou, China, November 18-20, 2011.
At this meeting, Dr. Wilson will review the role of TAP (Transporters Associated with Antigen Presentation) as a novel target for the development of vaccines for cancer and infectious disease, and the development pathway for TapImmune's technologies. Analysis of clinical samples indicate that a variety of solid tumors (breast, melanoma, ovarian, cervical and lung) have deficiencies in TAP levels, and that TAP levels correlate with lesion size, disease stage, metastatic potential and speed of disease progression. Different TAP genotypes also correlate with cervical cancer risk from oncolytic human papillomaviruses. Collectively, these studies indicate that abnormal expression of TAP genes are part of a widespread mechanism that can result in impaired antigen presentation and immune escape of malignant cells in a variety of tumors. Strategies to restore TAP expression, including clinical programs, will be discussed.
Key milestone PDF >>> http://www.tapimmune.com/_resources/media/TapImmune_Key_Milestone.pdf
Chart !!!
Contact Info
2815 Eastlake Avenue East
Suite 300
Seattle, WA 98102
United States
Phone: 206-336-5560
Company Description:
www.tapimmune.com TapImmune Inc., a development stage biotechnology company, focuses on the development and marketing of products specializing in the application of discoveries in cellular and molecular immunology and cancer biology to the development of proprietary therapeutics aimed at the treatment and eradication of cancer and prevention of infectious diseases. The company’s technologies are based on an understanding of the function of a protein pump known as ‘TAP’, which is located within cells and which is essential to the processing of foreign (microbial) or autologous antigens, and subsequent presentation to the immune system for eradication of the cancer or infected cell. Products and Technology in Development The company has developed its TAP Cancer Vaccine at the UBC Biomedical Research Centre under an agreement. This therapeutic cancer vaccine candidate, to be tested in preclinical toxicology studies, would include the patented use of the TAP-1 gene to restore the TAP protein, with the objective being to develop the TAP technology as a therapeutic cancer vaccine that would restore the normal immune recognition of cancer cells. The company has completed small animal pre-clinical animal testing of its TAP Cancer Vaccine to the extent that is required as a prerequisite for further preclinical toxicology analysis and investigational new drug (IND) application to the United States Federal Drug Administration. Strategic Alliances The company has entered into a five-year research license and option agreement with Crucell Holland B.V. (Crucell), whereby Crucell granted it a worldwide license for the research use of its packaging cell (PerC6) technology. The company signed a license agreement with the National Institute of Health (USA) for the use of the Modified Vaccinia Ankora (MVA) virus for the development of vaccines. It would license this technology for the development of prophylactic vaccines against infectious diseases. Competition The company’s major competitors include CellGenSys Inc., Dendreon Corp., Genzyme Molecular Oncology, and Transgene S.A. Significant Events In June 2010, the company has signed a licensing option agreement with Mayo Clinic Rochester for clinical development of a breast cancer vaccine technology. On August 4, 2010, TapImmune, Inc. announced that the company has signed a research and technology license option agreement with Mayo Clinic Rochester for the development of a smallpox vaccine technology.
Market / Customers
The company is currently developing TAP based vaccines for the oncology and prophylactic market. The global vaccine market is expected to grow from $13 billion in 2007 to $21 billion in 2010.
Website: http://www.tapimmune.com
Board maembers >>>> http://investing.businessweek.com/research/stocks/people/board.asp?ticker=TPIV:US
Latest news >>> http://www.biospace.com/company_profile.aspx?CompanyId=1004132
Ceo Profile:
Dr. Glynn Wilson, Ph.D. has been Executive Chairman of TapImmune, Inc. since June, 2009 and serves as its Chief Executive Officer. Dr. Wilson serves as President and Chief Executive Officer of Auriga Pharmaceuticals, a Speciality Pharmaceutical Company. Dr. Wilson serves as President of GW Group. He served as President of Auriga Laboratories Inc. until May 17, 2006 and its Chief Scientific Officer until August 25, 2006. He served as a Head for Drug Delivery of SmithKline ... Beecham Pharmaceuticals and Executive Vice-President for R&D of Tacora Corporation, he was responsible for conceiving and developing lead products (currently in Phase II clinical development), and providing leadership in the merging of Tacora Corporation with Access Pharmaceuticals. Dr. Wilson was the Worldwide Head of Drug Delivery of SmithKline Beecham from 1989 to 1994, and the Chief Scientific Officer of Tacora Corporation from 1994 to 1997. Dr. Wilson was the Vice-President, R&D, at Access Pharmaceuticals from 1997 to 1998, and the President and Chief Executive Officer of PharmaSpec Corporation from 1999 to 2000. In addition, he was a founding member of the Advanced Drug Delivery Group at Ciba-Geigy. He has been an adjunct professor, Pharmaceutics and Pharmaceutical Chemistry, at the University of Utah since 1994. He serves as Chairman of Medical and Clinical Board of Posh Cosmeceuticals Inc. He served as Chairman of the Board of Auriga Laboratories Inc. until May 17, 2006. He has been a Director of Genemax Corp. since February 2005 and TapImmune, Inc. since February 2005. He served as Director of Auriga Laboratories Inc. until May 17, 2006. He was a faculty member at Rockefeller University, New York, in the laboratory of the Nobel Laureates, Stanford Moore and William Stein from 1974 to 1979. Dr. Wilson obtained his Ph.D. in Biochemistry, at Heriot-Watt University, Edinburgh in 1972
Former Chairman and President
Auriga Laboratories Inc.
2005-Present
Executive Chairman, Chief Executive Officer, Member of Audit Committee and Member of Compensation Committee
TapImmune, Inc.
Ceo answers questions : >>> http://www.smallcapnetwork.com/TPIV-shows-significant-potential-plus-a-forward-looking-FDA-trade-catalyst/s/via/367/article/view/p/mid/1/id/53/
University, New York, in the laboratory of the Nobel Laureates, Stanford Moore and William Stein from 1974 to 1979. Dr. Wilson obtained his Ph.D. in Biochemistry, at Heriot-Watt University, Edinburgh in 1972
Former Chairman and President
Auriga Laboratories Inc.
2005-Present
Executive Chairman, Chief Executive Officer, Member of Audit Committee and Member of Compensation Committee
TapImmune, Inc.
Ceo answers questions : >>> http://www.smallcapnetwork.com/TPIV-shows-significant-potential-plus-a-forward-looking-FDA-trade-catalyst/s/via/367/article/view/p/mid/1/id/53/
"US Patent Office has issued Patent 7,994,146 entitled "Method of Enhancing an Immune Response". >>> http://www.patentgenius.com/patent/7994146.html
http://www.globenewswire.com/newsroom/news.html?d=236218
With the World Health Organization's recent vocal announcements of growing threats that multidrug-resistant and extensively drug-resistant forms of tuberculosis are spreading at an alarming rates in Europe, investors have once again begun to pay more attention to TPIV, which holds promise as both an anti-cancer and bio-defense play. TapImmune continues working with the likes of the Mayo Clinic and Aeras Foundation on vaccine candidates in both Cancer and Infectious Diseases.
The company has been quietly building solid relationships within industry because of the relevance of the TAP technology and BioMedReports continues to expect positive developments from the firm, particularly with CEO Dr. Glynn Wilson on the verge of presenting data from the clinic on TAP levels and its affect on disease progression. There is growing evidence now from around the world showing that TAP is indeed a key component in the antigen presentation process and where it is lacking or down regulated, disease progresses and prognosis is worse.
The Seattle based company's TAP-based prophylactic vaccine -- which initial tests indicate may increase the efficacy of targeted prophylactic vaccines by up to 1000 times -- may significantly improve the efficacy of many current prophylactic vaccines and enhance the creation of new ones in the fight against many pandemic infectious diseases.
A next generation smallpox vaccine is currently in preclinical development and the company has been busy working with Gregory Poland, the head of the Mayo Clinic's Vaccine Research Group, who is working to unite the fields of genomics and vaccinology. That work has come about, in part, because Poland and others have never been fully pleased with the existing vaccine paradigm.
Share StructureMarket Value1 $11,234,573 a/o Nov 18, 2011
Shares Outstanding 46,810,721 a/o Aug 01, 2011
http://www.otcmarkets.com/stock/TPIV/company-info
TPIV fact sheet PDF >>>> http://www.tapimmune.com/_resources/fact_sheet_nov_10.pdf
TPIV sec of state ACTIVE !!! http://nvsos.gov/sosentitysearch/CorpDetails.aspx?lx8nvq=yBFGvR8m9YhhFRCpanNMrQ%253d%253d&nt7=0
Chairman and CEO, Dr. Glynn Wilson, is an invited speaker at BIT's 2nd Annual World Congress on Immunodiseases and Therapy to be held in Guangzhou, China, November 18-20, 2011.
At this meeting, Dr. Wilson will review the role of TAP (Transporters Associated with Antigen Presentation) as a novel target for the development of vaccines for cancer and infectious disease, and the development pathway for TapImmune's technologies. Analysis of clinical samples indicate that a variety of solid tumors (breast, melanoma, ovarian, cervical and lung) have deficiencies in TAP levels, and that TAP levels correlate with lesion size, disease stage, metastatic potential and speed of disease progression. Different TAP genotypes also correlate with cervical cancer risk from oncolytic human papillomaviruses. Collectively, these studies indicate that abnormal expression of TAP genes are part of a widespread mechanism that can result in impaired antigen presentation and immune escape of malignant cells in a variety of tumors. Strategies to restore TAP expression, including clinical programs, will be discussed.
Key milestone PDF >>> http://www.tapimmune.com/_resources/media/TapImmune_Key_Milestone.pdf
Chart !!!
Join the InvestorsHub Community
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
